Preprint Article Version 1 This version is not peer-reviewed

Immunoinformatics-Guided Designing of an Epitope-Based Vaccine against Severe Acute Respiratory Syndrome-Coronavirus-2 Spike Glycoprotein

Version 1 : Received: 15 May 2020 / Approved: 16 May 2020 / Online: 16 May 2020 (17:07:43 CEST)

How to cite: Rakib, A.; Sami, S.A.; Paul, A.; Shahriar, A.; Tareq, A.M.; Emon, N.U.; Mimi, N.J.; Chowdhury, M.M.; Eva, T.A.; Chakraborty, S.; Shil, S.; Mily, S.J.; Emran, T.B. Immunoinformatics-Guided Designing of an Epitope-Based Vaccine against Severe Acute Respiratory Syndrome-Coronavirus-2 Spike Glycoprotein. Preprints 2020, 2020050271 (doi: 10.20944/preprints202005.0271.v1). Rakib, A.; Sami, S.A.; Paul, A.; Shahriar, A.; Tareq, A.M.; Emon, N.U.; Mimi, N.J.; Chowdhury, M.M.; Eva, T.A.; Chakraborty, S.; Shil, S.; Mily, S.J.; Emran, T.B. Immunoinformatics-Guided Designing of an Epitope-Based Vaccine against Severe Acute Respiratory Syndrome-Coronavirus-2 Spike Glycoprotein. Preprints 2020, 2020050271 (doi: 10.20944/preprints202005.0271.v1).

Abstract

Currently, with a large number of fatality rates, coronavirus disease-2019 (COVID-19) has emerged as a potential threat to human health worldwide. It has been well-known that severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is responsible for COVID-19 and World Health Organization (WHO) proclaimed the contagious disease as a global pandemic. Researchers from different parts of the world amalgamate together inquest of remedies for this deadly virus. Recently, it has been demonstrated that the spike glycoprotein (SGP) of SARS-CoV-2 is the mediator behind the entrance into the host cells. Our group has comprehensibly analyzed the SGP of SARS-CoV-2 through multiple sequence analysis along with the phylogenetic analysis. Further, this research work predicted the most immunogenic epitopes for both B-cell and T-cell. Notably, we focused mainly on major histocompatibility complex (MHC) class I potential peptides and predicted two epitopes; WTAGAAAYY and GAAAYYVGY, that bind with the MHC class I alleles which are further validated by molecular docking analysis. Furthermore, this study also proposed that the selected epitopes were shown availability in a greater range of the population. Hence, our study comes up with a strong base for the implementation of designing novel vaccine candidates against SARS-CoV-2, however adequate laboratory works will need to be conducted for the appropriate application.

Subject Areas

COVID-19; SARS-CoV-2; de novo vaccine; epitope; immunity

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.